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Abstract: Consensus interferon (CIFN) is an artiﬁ  cially engineered interferon that reﬂ  ects 
most of the human genotype 1 interferons and shows a higher biological and antiviral capacity 
in vitro. It has been used internationally to treat patients with chronic hepatitis C (HCV) 
infection before pegylated IFN became available. To mimic the half-life of PEG-IFN it has 
to be administered on a daily basis. The gold standard in the treatment of hepatitis C is well 
established and recommended. Today patients are being treated with a combination therapy 
of pegylated IFN and ribavirin. Length and dosage of therapy depends on the genotype of the 
virus. Patients with genotype 1 and 4 and high viral load should be treated for 48 weeks; for 
patients with these genotypes along with either low viral load or early virological response, 
therapy for 24 weeks is sufﬁ  cient. Patients with genotype 2 and 3 should be treated for up to 
24 weeks. However, daily dosing of IFN-α, eg, CIFN, resulting in a higher cumulative dosage, 
might be beneﬁ  cial and more efﬁ  cacious in some chronic HCV-infected patients. Patients with 
genotype 1, having initially high viral load (800,000 IU/mL) and showing advanced liver 
disease with progressive ﬁ  brosis or even cirrhosis comprise the difﬁ  cult-to-treat in order to 
overcome the infection. This review summarizes and critically discusses the published data on 
the treatment of HCV with CIFN.
Keywords: CIFN, interferon-alfacon-1, early virological response, sustained virological 
response, PCR, pegylated IFN-α-2a/b
Background
Under physiological conditions, interferon-α (IFN-α) is a key cytokine produced by 
virtually all cells in the mammalian organism in response to a variety of bacterial and 
viral stimuli. In response to viral infection, IFN-α produced by the infected target cells 
induces a number of cellular genes involved in inhibition of viral replication. In addi-
tion, IFN-α is secreted by stimulated NK-cells and T-cells, and exerts a multitude of 
immune stimulatory effects of innate and adaptive immunity (Pestka 1997). Examples 
of IFN-stimulated gene products include 2'5'oligoadenylate synthetase (2'5'OAS) and 
ß2-microglobulin.
The current standard to treat patients with chronic hepatitis C (HCV) infection is 
IFN-α with or without ribavirin, and great advances have been achieved (Cornberg 
et al 2002). So far 2 allelic α-2 species, IFN-α-2a and IFN-α-2b, have been used. 
Introduction of pegylated IFN in 2001 showed a slight increase in the overall sus-
tained virological response rates (approximately 55%) compared with conventional 
IFN-α (36%) (Manns et al 2001; Fried et al 2002). However, recent studies showed that 
these response rates depend on several factors, including HCV genotype, baseline viral 
load, ethnicity, body weight and presence of advanced liver disease (Manns et al 2001). 
More than 75% of patients in western Europe are infected with genotype 1 showing a 
high viral load and these patients are so called “difﬁ  cult to treat” and therefore remain at Biologics: Targets & Therapy 2008:2(4) 636
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risk not to respond to standard HCV treatment (Di Bisceglie 
and Hoofnagle 2002). There is still a need for improved 
therapies, especially for difﬁ  cult to treat patients such as 
HCV-genotype 1 infected individuals, patients with liver 
cirrhosis, or patients of any genotype who did not respond 
to a previous IFN-α-based therapy (Shiffman 2004). Even 
the new standard therapy of pegylated IFN-α (PEG-IFN-α) 
in combination with ribavirin is not very effective for the so 
called non-responder patients. Relapsed patients may beneﬁ  t 
from retreatment but patients with HCV-genotype 1 who were 
true non-responders to IFN and ribavirin demonstrated only 
12% sustained virological response (SVR) with PEG-IFN 
and ribavirin as second-line therapy (Shiffman 2004; Poynard 
et al 2005). However, viral eradication should be still the ﬁ  rst 
achievable goal whenever possible.
IFN-alfacon-1
IFN-alfacon-1, a non-natural recombinant interferon, is a 
second-generation cytokine that was engineered to contain the 
most frequently occurring amino acids among the non-allelic 
IFN-α subtypes in humans (Blatt et al 1996) to form a con-
sensus molecule. In rhesus monkey LLC cell line and golden 
Syrian hamster BHK cell line in vitro studies have shown that 
IFN-alfacon-1 causes a more dramatic decrease of HCV-RNA 
compared with IFN-α-2b (Sjogren et al 2007) and showed a 
10-fold higher antiviral efﬁ  cacy (Blatt et al 1996). These stud-
ies have been conﬁ  rmed in further in vivo studies.
Because the serum levels of consensus IFN (CIFN) 
given 3 times a week drops almost below the detection 
limit by the next dose, daily dosing of CIFN has been 
used in some studies (Kaiser et al 2005). In some studies, 
a high initial dosing has been used as induction therapy to 
reduce viral load and obtain an early virological response 
(EVR), reasoning that this would lead to a higher SVR 
(Lam et al 1997). CIFN is approved for use in the US at 
the dose of 15 μg and in Europe at the dose of 9 μg sc in 
therapy-naive HCV infected patients 3 times a week (tiw) 
for up to 6 months.
To date, several controlled but small studies have been 
published investigating the role, safety and efficacy of 
IFN-alfacon-1 in patients with chronic HCV who were 
either naïve to antiviral therapy or did not respond to 
antiviral combination therapy with IFN-α or PEG-IFN-α in 
combination with ribavirin.
However, due to economic reasons and after a merger 
of the former company distributing CIFN the drug has 
been taken off the market by the manufacturer, at least in 
Germany, in 2006.
Methods
This article reviews the results of recent published and 
preliminary studies involving IFN-alfacon-1 and ribavirin in 
the treatment of chronic HCV. The published literature was 
identiﬁ  ed using a MEDLINE/PubMed search with secondary 
review of cited publications. All articles have been carefully 
read and are critically discussed.
Results
In an early multicenter, randomized, controlled, double-
blind, phase III study with 704 patients with chronic HCV 
infection, Tong et al (1997) compared CIFN at doses of 3 μg 
and 9 μg to a standard regimen of recombinant IFN-α-2b at 
15 μg 3 times weekly for 24 weeks with a 24 week follow-up 
period in a therapy-naïve cohort. The beneﬁ  cial effect was 
greater with the 9 μg dose than the 3 μg dose. The sustained 
alanine aminotransferase (ALT) and HCV RNA response 
rates were 20.3% and 12.1%, respectively, in the 9 μg CIFN 
cohort and 19.6% and 11.3%, respectively, in the 15 μg IFN 
IFN-α-2b cohorts (Tahara et al 2007). Patients with HCV 
genotype-1 did respond better in the high dose CIFN cohort 
(24% vs 15%). Improvements in liver histology were noted 
in all 3 treatment groups. The adverse-event proﬁ  les were 
similar in all cohorts.
In a subsequent multicenter trial, a higher dose of CIFN 
(15 μg) was reinstituted in patients who either had relapsed 
or were non-responders to prior CIFN or IFN-α-2b therapy. 
Patients were randomized to receive 24 or 48 weeks of 
retreatment followed by 24 weeks of observation. The SVR 
were 28% in relapsers and 5% in non-responders, respec-
tively, in the 24-week retreatment cohort and 58% and 
13%, respectively, in the 48-week retreatment cohort, indi-
cating that longer treatment in relapsers and non-responders 
results in a better overall response rate. The administration of 
9 μg or 15 μg CIFN was well tolerated and adverse effects 
were similar to those of IFN-α-2b. 15 μg of CIFN provided 
meaningful response in both relapsers and non-responders 
(Keeffe and Hollinger 1997).
In a randomized study of Pockros et al (1998), 
704 patients have been treated with CIFN. Two-hundred 
and thirty-two patients received 3 μg CIFN tiw, 232 patients 
received 9 μg CIFN tiw, and 240 patients were treated 
with IFN-α-2b at 3 MU tiw. Fifty-three percent of patients 
(120/225) who had normal ALT concentrations showed 
undetectable HCV RNA at the end of treatment. At the end 
of follow up, 47% presented a sustained virological response. 
In contrast, of the patients with undetectable HCV RNA, 75% 
(120/161) and 84% (51/61) had normal serum ALT activities Biologics: Targets & Therapy 2008:2(4) 637
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Table 1 Studies investigating the role of IFN-alfacon-1 and ribavirin in the treatment of therapy-naïve patients with chronic hepatitis C
Author Method No patients Dosing regimen Results EVR, SVR Conclusion
Hwang et al 
1999
Randomized, 
double-blind, 
controlled
75 chinese 9 or 3 μg of CIFN 
tiw vs placebo for 
24 weeks
EOT response was 
56%, 42.3% and 4.2% 
at week 24;
Safe and effective to 
reduce ALT and HCV 
RNA concentration
SVR at week 48 
40%, 11.5% and 0%
Jensen et al 
1999
Multicenter 
phase 3
472 US 9 μg CIFN vs 3 
MU IFN-α-2a tiw 
for 24 weeks
EOT response was 
51% vs 31%
Genotype and 
baseline viral load are 
independent factors 
predicting response
Yao et al 2000 Multicenter, 
randomized, 
controlled
187 Chinese 15 or 9 μg CIFN 
or 3 MU IFN-α-2a 
tiw for 24 weeks
SVR response was 
55.7% vs 49.2% 
vs 39.3%
CIFN is safe and 
effective, 15 μg CIFN 
is more effective than 
3MU IFN-α-2a
Kao et al 2000 Multicenter 48 Taiwanese 9 μg vs 3 μg. of 
CIFN tiw for 24 
weeks
EOT 48 vs 44%, SVR 
16 vs 12%
9 μg CIFN is safe and 
effective
Hwang et al 
2001
Multicenter, 
open-label
35 Chinese 15 vs 9 vs 3 μg 
CIFN vs placebo 
tiw
SVR 66% vs 20% vs 
36% vs 31%
15 μg CIFN is 
similarly effective as 
compared with 9 μg 
CIFN, and there is 
beneﬁ  t for pre-
treated patients
Layden et al 
2002 (31)
Multicenter 173 US Induction therapy 
for 4 wks followed 
by 9 μg CIFN tiw
SVR: 11% in GT-1 
and 41 in non-GT-1 
patients
Induction dosing 
of CIFN did not 
improve SVR rates
Pockros et al 
2003 (37)
Randomized 
pilot study
40 US 9 μg CIFN alone 
daily vs 9 μg CIFN 
daily plus RBV for 
48 weeks
GT-1 response 50 
(10/20) vs 55% 
(11/20)
Trend towards 
higher response 
rate (compared 
with monotherapy), 
enhanced SVR by 
combined therapy; 
daily dosing seems 
feasible
Fattovich et al 
2003 (15)
Open-label, 
randomized 
study
193 Italian 9 or 18 μg CIFN 
tiw plus RBV daily 
for 24 or 48 weeks 
(GT-1)
SVR GT-2/3 is 69 
vs 66%, GT-1 40 
vs 36%; overall 
SVR was 67 vs 38% 
(GT-2/3 vs GT-1)
Higher dosing 
of CIFN did not 
increase SVR rate
Saito et al 
2006 (40)
Open-label, 
randomized
28 Japanese CIFN 9 μg/daily 
prior induction 
therapy with/with-
out IFN-β (2 × 3 
million IU/daily)
SVR was 81.3% with 
induction vs 58.3% 
without induction, 
SVR with HVL was 
70 vs 75%
Induction therapy 
has no beneﬁ  cial 
effect on efﬁ  cacy, high 
drop-out rates, lot of 
adverse events
Witthöft et al 
2007
Open-label, 
pilot-study
58 German 18 μg of CIFN 
daily for 8 weeks 
followed by 9 μg 
CIFN daily plus 
RBV for 16 or 40 
weeks
SVR in 48% of 
patients with GT-1; 
62% of all patients 
responded at week 
24 or 48
Rate of EOT is lower 
compared with 
standard therapy; 
daily CIFN is safe and 
tolerable
Abbreviations: CIFN, consensus interferon; EOT, end of treatment; GT-1, genotype 1; GT-2/3, genotype 2 or 3; HVL, high viral load; IFN, interferon; IU, international units; LVL, 
low viral load; RBV, ribavirin; SVR, sustained virological response; tiw, 3 times weekly.Biologics: Targets & Therapy 2008:2(4) 638
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at the end of treatment and post-treatment observation period, 
respectively. Most patients with undetectable HCV RNA 
had normal ALT values. In contrast, only half of the patients 
with normal ALT values were negative for HCV. At the end 
of treatment, HCV RNA response predicted sustained viro-
logical response better than did the ALT response (Pockros 
et al 1998).
In a large multicenter trial, 472 patients have been treated 
with either CIFN or IFN-α-2b for up to 6 months. The pur-
pose of the analysis was to compare the efﬁ  cacy parameters 
(eg, clearance of HCV RNA, normalization of ALT values, 
and improvement of histology) in non-ﬁ  brotics, ﬁ  brotics, and 
cirrhotics. Patients with cirrhosis and chronic HCV infection 
showed the same beneﬁ  t from IFN treatment as non-cirrhotic 
patients when efﬁ  cacy was assessed by clearance of serum 
HCV RNA or by histological beneﬁ  t. Sustained virological 
responses were similar when measured among non-ﬁ  brotic 
(11%), ﬁ  brotic (13%), and cirrhotic (11%) patients. Cirrhotic 
patients had a lower sustained ALT response rate (12%) 
than did non-ﬁ  brotic patients (23%). Ninety percent of non-
ﬁ  brotics but only 71% of ﬁ  brotics and 67% of cirrhotics 
who sustained a virological response showed normalized 
ALT. In conclusion, liver cirrhosis should not be a reason 
for excluding patients from therapy, because both cirrhotic 
and ﬁ  brotic HCV patients beneﬁ  ted from IFN therapy, not 
only by clearance of the virus but by improvement in liver 
histology (Everson et al 1999).
In Canada, 467 patients chronically infected with HCV 
were treated with either CIFN at 9 μg or 3 MU IFN-α-2b tiw. 
Eighteen percent of patients showed a breakthrough of HCV-
RNA, and 19% showed a breakthrough of ALT. When the 
patients who were initially non-responders to IFN treatment 
were re-treated with CIFN (15 μg) for 12 months, 27% of 
those with viral breakthroughs had a sustained viral response 
compared with 8% in prior non-responders without break-
throughs. Sustained ALT responses were observed in 39% 
with breakthroughs compared with 10% in those without 
breakthroughs. Heathcote et al (1999) concluded that prior 
non-responders with breakthroughs have a greater chance of 
responding to retreatment than do non-responders without 
breakthrough (deﬁ  ned as re-occurrence of the virus through-
out therapy). However, repeated HCV-RNA testing has to be 
conducted during therapy.
Genotyping has been shown to predict response to IFN, 
but it is expensive. HCV serotyping is less expensive and 
simple, and may be equally useful. In a large multicenter 
trial, 704 patients with chronic HCV infection treated with 
CIFN 3 μg, 9 μg or IFN-α-2b tiw, the end of treatment HCV 
RNA rate of response (deﬁ  ned as undetectable serum on two 
consecutive assessments) was 29% for serotype 1 vs 24% 
for genotype 1 after CIFN. The corresponding rates with 
IFN-α-2b were 14% vs 15%, respectively. Independently of 
treatment, patients infected with serotype or genotype 2 or 
3 had a better therapeutic response than those infected with 
genotype 1 (Keeffe et al 1999a).
Patients with genotype 1 showed lower response rates 
than those with genotype 2 and 3. In a multicenter trial, 
472 patients with chronic HCV treated with either CIFN 
or IFN-α-2b, neither virological sustained responders 
nor relapsers differed in the pattern of serum HCV RNA 
decrease based on genotype. Relapsers had a slower rate of 
serum HCV RNA decrease than did virological sustained 
responders. HCV genotype 1 treated with CIFN had a greater 
decrease in HCV RNA during therapy than did patients 
treated with IFN-α-2b. However, there was no difference in 
the magnitude of serum HCV RNA decrease between the two 
IFN treatments for patients with genotype 2 or 3 (Keeffe 
et al 1999b). Patients who relapsed after a prior treatment 
with CIFN at doses of either 3 or 9 μg may beneﬁ  t from a 
re-treatment with 15 μg.
IFN is a potent cytokine with multiple targets. From 
previous studies it is very well known that patients being 
treated with IFN-α for chronic HCV infection may develop 
either hypo- or hyperthyroidism with destructive thyroiditis. 
In a prospective Italian trial, 51 patients with chronic HCV 
infection and without pre-existing thyroid disease received 
antiviral therapy with IFN-α-2b plus ribavirin or CIFN plus 
ribavirin. Ten out 36 patients developed thyroid autoimmu-
nity during therapy with IFN-α-2b. Under CIFN treatment, 
5 out of 15 patients developed thyroid autoimmunity and 
stopped antiviral treatment. All patients did recover from 
thyroidism without speciﬁ  c treatment. However, CIFN may 
induce thyroid autoimmunity in a larger proportion compared 
with IFN-α-2b (Mazziotti et al 2002).
In a small study in Brazil, 14 patients were treated with a 
rather high dose of CIFN of 15 μg plus ribavirin (1000 mg) 
daily for 4 weeks followed by 9–15 μg every second day 
for 44 weeks. In 10 patients where was a marked decrease 
of viral load at week 2, and 10 patients showed a loss of 
HCV RNA by the end of treatment. SVR was seen in 4 out 
of 11 patients (36%) who completed 24 weeks of follow up 
(Da Silva et al 2002).
Patients with genotype 2 and 3 may respond better to 
antiviral therapy compared to genotype 1 patients. Fattovich 
et al (2003) determined the efﬁ  cacy and safety of different 
doses of CIFN plus ribavirin in the initial treatment of chronic Biologics: Targets & Therapy 2008:2(4) 639
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HCV infection. Patients with GT 2/3 received either 9 μg 
(group A) or 18 μg (group B) of CIFN tiw plus ribavirin 
for 24 weeks. Genoytype 1 patients were treated with 9 μg 
(group C) or 18 μg (Group D) for 48 weeks. In an ITT analy-
sis, the sustained virological response at 24-week follow up 
was 69% and 66% for groups A and B and 40% and 36% 
for groups C and D. The overall SVR was 67% and 38% in 
patients with genotype 2/3 and 1, respectively. Therefore, a 
higher CIFN dose does not increase SVR.
Despite the genotype, the response to antiviral treatment 
depends also on a different racial and ethnic background. 
Three-hundred and thirty patients with chronic HCV infec-
tion were treated with CIFN as a daily induction therapy at 
15 μg daily for 30 days followed by a randomized 1:1 ratio 
of either 9 or 15 μg every other day. Thirty percent of 
patients were non-white. An overall SVR was achieved 
in 24% of white, 12% of Hispanic, and 4% of African-
American patients. Fifteen percent of white and 13% of 
Hispanic genotype 1 patients achieved SVR compared with 
2% of African-American. Surprisingly, a SVR of 50% and 
40% was achieved in African-American and white genotype 
2 patients, compared with 10% in Hispanic patients (Gaglio 
et al 2004).
Combination therapy with PEG-IFN (α-2a or -2b) and 
ribavirin is the most effective therapy for patients with HCV 
infection. However, responses are less than optimal in some 
subgroups of patients. Viral kinetics might be useful to predict 
therapeutic outcome. Rapidity of virological response seems 
to be a better predictor than genotype and initial viral load. 
Weight-based dosing of ribavirin has emerged as another 
important consideration. This strategy seems to be the most 
important for difﬁ  cult-to-treat patients with genotype 1 or 
advanced ﬁ  brosis, and for African Americans, and is possibly 
important for patients who have genotype 3 and high viral 
load. Re-treatment of non-responders with IFN-based therapy 
has been associated with low rates of sustained virological 
response. CIFN might offer a new option for patients who 
did not achieve an early treatment response to standard or 
PEG-IFN plus ribavirin (Brown 2007).
In an open-label single-center study, 58 patients with 
chronic HCV were treated with a high-dose induction therapy 
with CIFN and ribavirin. The rationale for daily dosing in 
this study was based on the observation that serum levels of 
IFN-α given 3 times a week were dropping almost below the 
detection limit every other day and therefore reducing the 
antiviral capability. High initial dosing reduced the viral load 
even further and EVR yielded a higher SVR than 9 μg daily 
(Lam et al 1997).
A more recent study compared the virologic response 
with CIFN or PEG-IFN-α-2b plus weight-based ribavirin 
in patients chronically infected with HCV genotype 1. The 
ITT analysis showed a response of 37% vs 41%, respectively, 
with response rates of 42% vs 44% observed in an analysis 
of the per-protocol population. Tolerability of the 2 treatment 
regimens was similar. In conclusion, both treatment regimens 
were safe and gave a similar antiviral response. If CIFN is 
administered daily rather than 3 times weekly, eradication 
of HCV could be achieved in a larger proportion of patients 
infected with HCV genotype 1 (Sjogren et al 2007).
Even though enormous advances in treating patients with 
chronic hepatitis C have been achieved over the last decade 
(Cornberg et al 2007), there is still a need for improved 
therapies, especially for the difﬁ  cult-to-treat patients such 
as HCV genotype 1-infected individuals, patients with liver 
cirrhosis, or patients who did not respond to a previous 
IFN-α-based therapy (Shiffman 2004). In an open label 
pilot study Cornberg et al (2007) investigated the efﬁ  cacy of 
CIFN plus ribavirin on viral kinetics, sustained virological 
response, and histological response in HCV non-responders. 
Seventy-seven patients were enrolled to receive CIFN given 
daily in combination with ribavirin 1000/1200 mg. An 
8-week induction-dosing regimen of 18 μg CIFN, followed 
by 9 μg for 40 weeks was compared with 9 μg CIFN for 
48 weeks. Ninety percent of patients were infected with HCV 
genotype 1. Overall, 82% of the patients demonstrated an 
EVR, 65% had an end of treatment response, and the SVR 
was 30%. IFN/ribavirn non-responders demonstrated a SVR 
of 22%. Induction dosing resulted in a greater ﬁ  rst-phase 
HCV RNA decay, which, however, did not translate to a 
better SVR, presumably due to more dose modiﬁ  cations. 
High ALT, younger age, and second-phase viral kinetics were 
associated with SVR. Only sustained responders and relapse 
patients showed an improved liver histology. In conclusion, 
daily dosing of CIFN plus ribavirin may be a promising 
concept for selected non-responders before considering thera-
pies that are anti-viral but not curative. However, motivation 
and compliance are requisite and a CIFN induction is not 
required (Cornberg et al 2006).
Despite advances in the therapy of chronic HCV, a large 
number of patients do not respond to current therapies. In 
an open-label, prospective, randomized, controlled study, 
128 patients with chronic HCV were treated either with 
CIFN 15 μg tiw, plus ribavirin 1000 mg/day, or 3 MU 
IFN-α-2b tiw plus ribavirin 1000 mg/day for 48 weeks. 
The endpoint of the study was a SVR (deﬁ  ned as undetect-
able HCV RNA at 24 weeks post 48 weeks of treatment). Biologics: Targets & Therapy 2008:2(4) 640
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Overall, 57% of subjects in the CIFN/ribavirin group 
achieved a sustained viral response, compared with 40% of 
subjects in the IFN-α-2b/ribavirin group. In the subset of 
subjects with a high viral load, HCV RNA was successfully 
eradicated in more individuals who received CIFN/ribavirin 
than subjects who received IFN-α-2b/ribavirin (57 vs 31%). 
Among individuals with genotype 1 and high viral load, the 
sustained antiviral response was signiﬁ  cantly higher with 
CIFN/ribavirin than with IFN-α-2b/ribavirin (46 vs 14%). In 
conclusion, the study demonstrated that the combination of 
CIFN and ribavirin provides a signiﬁ  cantly better treatment 
response than the combination of IFN-α-2b and ribavirin in 
chronic HCV subjects infected with genotype 1 and high 
viral RNA load (Sjogren et al 2005).
Recently, one study showed that daily dosing of 9 μg 
CIFN signiﬁ  cantly increased the SVR compared with a 
9 μg tiw regimen (Rustgi et al 2005). Preliminary data from 
a single center study suggested that daily dosing of CIFN in 
combination with ribavirin can achieve SVRs of 38%–45% 
in non-responders to standard IFN and ribavirin depending 
on the CIFN dose (Kaiser et al 2005). High-dose-induction 
therapy seemed to further improve SVR in this study (Kaiser 
et al 2005), even though it was not effective in studies with 
standard IFN-α-2a or -2b (Carithers et al 2000; Fried et al 
2000; Hadziyannis et al 2001). In a recent study it has been 
assessed that the ﬁ  rst-phase viral kinetics in 20 previously 
non-responders after a single dose of 15 μg or 30 μg CIFN 
and demonstrated a signiﬁ  cantly sharper decline (0.8 vs 1.5) 
of the HCV-RNA with the higher dose after 24 hours (Cotler 
et al 2003). Sjogren et al (2005) have shown that combina-
tion therapy of CIFN and ribavirin provides a signiﬁ  cantly 
better treatment response compared with the combination 
of IFN-α-2b and ribavirin in chronic HCV subjects infected 
with genotype 1 and a high viral load.
Patients who failed prior treatment with IFN-α may 
benefit from a re-treatment with CIFN and ribavirin. 
One-hundred and three patients (69 non-responders 
and 34 relapsers) were randomly assigned to high-dose 
induction therapy (group A) (CIFN 27 μg → 9 μg daily 
for 24 weeks, 9 μg for 24 weeks) or low-dose-treatment 
(group B) (CIFN 18 μg tiw for 12 weeks, followed by 9 μg 
tiw for 36 weeks); each with ribavirin at 800 mg daily. Non-
responders treated with high-dose induction had a higher 
early virological response rate (63% vs 39%). The initial 
positive effect was lost during the last 24 weeks. Relapse 
patients revealed SVR in 70% and 38% in groups A and B. 
Treatment was well tolerated with side effect-related pre-term 
discontinuation in 8% and 5%. Viral elimination rates might 
be further increased by continuous daily administration of 
CIFN and weight-based ribavirin (Böcher et al 2006).
We recently compared in a single center study the 
safety and efﬁ  cacy of high dose daily CIFN (18 μg daily 
for initially 8 weeks followed by 9 μg daily) plus ribavirin 
and PEG-IFN-α-2b plus ribavirin in therapy-naïve patients 
with chronic HCV infection (Witthöft et al 2007). Treatment 
regimen with PEG-IFN-α-2a and ribavirin is superior for 
SVR and tolerablity. In genotype 1 the SVR was 58% vs 
48%, and in genotype 2 and 3, 85% vs 73%, respectively. Side 
effects are more common and more severe in patients taking 
CIFN daily resulting in a higher drop out rate (15.4% vs 0%) 
and lower SVR. CIFN in combination with ribavirin might 
be favorable for difﬁ  cult-to-treat patients with high viral load 
or non-response to conventional standard therapy. Patients 
with genotype 1 and low viral load (800,000 IU/mL) did 
respond in both arms signﬁ  cantly better to antiviral treatment 
compared with those with high viral load.
The side effects of IFN-α are farily similar: inﬂ  uenza-like 
symptoms, headache, cough, leucopenia and thrombocy-
topenia, hyper- or hypothyroidism, multiple effects on the 
immune system, and development of auto-antibodies. These 
side effects may sometimes be dose-dependent. Systemic 
sclerosis is an autoimmune disease that might be triggered by 
the IFN-α and may cause a stiffness of the skin but can affect 
the heart and the gastrointestinal tract as well. A few cases 
have been reported after the treatment of HCV with IFN-α-2a 
or 2b and also with IFN-alfacon-1 (Tahara et al 2007).
Discussion
Combination of pegylated IFN-α-2a or 2b plus ribavirin is 
the gold standard in the therapy of chronic viral HCV infec-
tion. Most of the studies that have been reviewed are small 
in patient numbers and have dealt with IFN-alfacon-1 plus 
ribavirin alone, some have compared its efﬁ  cacy with that of 
IFN-α-2a plus ribavirin, but only a few trials have compared 
CIFN with the newer standard of care such as PEG-IFN-α-2a 
or 2b plus ribavirin.
But even with this newer pegylated regimen only 
50% (eg, in genotype 1 and 4) or up to 80% (eg, in geno-
type 2 and 3) of patients will achieve a sustained virological 
response (Fried et al 2002). However, comparing studies is 
always a problem. Deﬁ  ning the patient who is really a non-
responder to prior therapy or who was just not compliant 
makes a big difference. Adherence is an important factor for 
the success of the treatment (Fattovich et al 2003). Therapies 
that induce severe side effects might in the end be less effec-
tive despite higher antiviral efﬁ  cacy. Head-to-head studies Biologics: Targets & Therapy 2008:2(4) 641
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Table 2 Studies investigating the role of IFN-alfacon-1 and ribavirin in patients with chronic hepatitis C non-responding to or relapsing 
after therapy with conventional interferon and ribavirin
Author Method No patients Dosing regimen Results EVR, SVR Conclusion
Heathcote et al 
1999
Open-label, 
multicenter
176 Canadian 
(86 break-
through, 90 non-
responder) after 
9 μg CIFN or 
3 MIU IFN-α-2a 
tiw for months
15 μg CIFN daily 
for 12 months
SVR in 27 vs 8% 
(break-through vs non-
responder), sustained 
ALT response in 
39 vs 10%
Prior non-responders 
with breakthrough 
responded better than 
non-responders without 
prior breakthrough
Da Silva et al 
2002
Open-label 14 Brazilian 
non-responder 
to IFN-α-2a 
plus RBV
15 μg CIFN plus 
RBV daily for 
4 weeks followed 
by 9–15 μg CIFN 
plus RBV daily for 
44 weeks
EOT in 71% (10/14), in 
GT-1 EOT of 67%, SVR 
in 4 of 11 patients (36%)
Rapid decrease of viral 
load, high SVR of 36% 
after 24 weeks of 
follow up
Moskovitz et al 
2003
Open-label 24 Canadian 
non-responders
15 μg CIFN daily 
in non-responders 
for 48 weeks
SVR in 2 patients (8%) 
after 72 weeks
Loss of RNA at EOT 
in 50% of patients, SVR 
only 8%
Cornberg et al 
2006
Open-label, 
pilot study
77 German 
non-responders
8 week induction 
with 18 μg CIFN 
daily plus RBV 
followed by 9 μg 
CIFN daily or 
9 μg CIFN plus 
RBV for 48 weeks
Overall EVR of 82%, 
EOT of 65% and SVR of 
30%, induction therapy 
resulted in better SVR 
rate
Daily CIFN may be 
promising in selected 
non-responders
Böcher et al 
2006
Open-label 103 german (69 
non-responders, 
34 relapsers)
27 μg CIFN daily 
as induction 
followed by 9 μg 
CIFN tiw for 
24 weeks or 
18 μg CIFN tiw 
for 12 weeks 
followed by 9 μg 
CIFN plus RBV
EVR 63 vs 39%, but SVR 
26% in both groups
Induction of consid-
erable SVR rates in 
non-responders, but 
weight-based RBV might 
further increase SVR
Alaimo et al 
2006
Open-label, 
randomized
34 Italian non-
responders with 
GT-1
9 μg CIFN plus 
RBV tiw vs 18 μg 
CIFN plus RBV 
tiw for 52 weeks
EVR 35 vs 32%, EOT 
35 vs 35%, SVR 27.3 
vs 26.1%
Low SVR rate indepen-
dent of dosage, scarce 
tolerability
Aladag et al 
2006
Open-label 11 Turkish non-
responders and 
relapsers
Re-treatment 
with CIFN mono-
therapy with daily 
dosing (9 μg) in 
prior CIFN non-
responders or 
relapsers
EOT in NR 60 %, EOT 
in relapsers 83%; SVR in 
NR 40%, SVR in relaps-
ers 66%
CIFN in combination 
with RBV needs further 
investigation for difﬁ  cult-
to-treat patients
Abbreviations: CIFN, consensus interferon; EOT, end of treatment; GT-1, genotype 1; GT-2/3, genotype 2 or 3; HVL, high viral load; IFN, interferon; IU, international units; 
LVL, low viral load; MIU, million international units; NR, non-responder, RBV, ribavirin; SVR, sustained virological response; tiw, 3 times weekly.Biologics: Targets & Therapy 2008:2(4) 642
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comparing PEG-IFN-α-2a or 2b plus ribavirin and CIFN 
plus ribavirin are completely lacking.
Dosing of CIFN varies from country to country. In the 
US, CIFN is being used at concentrations of 15 μg tiw and in 
Germany 9 μg tiw is approved. However, these doses might 
be far too low to achieve a higher SVR rate in chronically 
infected patients. Because of the pharmacology and kinetics 
of CIFN, its serum levels change daily; high levels after 
subcutaneous injection are followed by a day of low serum 
concentrations. Even though CIFN shows a 10-fold stronger 
antiviral effect in vitro compared with IFN-α-2a (Sjogren 
et al 2007), these kinetics are the major disadvantage of the 
3-times-weekly treatment schedule with CIFN, giving the 
virus a chance to recover and multiply, and thus may lead 
to viral breakthrough or viral resistance. High-dose induc-
tion protocols with CIFN and ribavirin, using up to 27 μg 
daily, are quite promising but are associated with severe side 
effects, eg, inﬂ  uenza-like symptoms, myalgia, leucopenia, 
thrombocytopenia, neutropenia, depression, and weight loss, 
associated with higher drop-out rates and requiring dose mod-
iﬁ  cations more often (Kaiser et al 2005; Witthöft and Fuchs 
2007). Drug companies are aware of this shortcoming and 
strategies linking CIFN to a larger molecule like polyethylene 
glycol or albumin are under development. This formula may 
extend the stay of the molecule in the serum, and therefore 
enhance its antiviral capability and efﬁ  cacy. A once-weekly 
dosing of CIFN may increase compliance in patients, result-
ing in higher sustained virological response rates.
However, subcutaneous injection every other day 
followed by IFN-speciﬁ  c side effects such fever and inﬂ  u-
enze-like symptoms does not make CIFN a favorable drug for 
patients compared with PEG-IFNs. So far, CIFN given even 
at high-dose induction therapy in non-responders was well 
tolerated by treatment-experienced and motivated patients 
(Cornberg et al 2006).
As expected, patients with advanced ﬁ  brosis or even 
cirrhosis showed low response, and these patients, who 
would beneﬁ  t most from curative antiviral treatment, have 
the worst outcome (Cornberg et al 2006). These patients 
may beneﬁ  t from a low-dose IFN maintenance treatment to 
prevent complications of liver cirrhosis (Curry et al 2005; 
Erhardt et al 2007).
Conclusion
PEG-IFNs plus ribavirin are standard of care for the treat-
ment of naïve patients with chronic HCV infection, and 
long-term maintenance therapy with PEG-IFN might be the 
therapy of choice for cirrhotic patients (Kaiser et al 2005). 
However, selected and highly motivated patients with less 
ﬁ  brotic damage of the liver, and non-responders to previous 
therapy, may consider alternative therapies such as daily 
dosing of CIFN plus ribavirin in order to achieve sustained 
viral treatment, as long as a the pegylated formula of CIFN or 
polymerase or protease inhibitors are not available. CIFN has 
demonstrated efﬁ  cacy in the re-treatment of non-responders 
and relapsers. Although the optimal duration of treatment 
and the beneﬁ  ts and safety of maintenance therapy have not 
been determined, an extended duration is likely needed. The 
antiviral efﬁ  cacy of CIFN combined with a once-weekly 
injection of, for example, a PEG-CIFN plus ribavirin might 
be another therapeutic option in the near future.
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